Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4609-4619

  Cinelli, Maris A ^a   Morrell, Andrew ^a   Dexheimer, Thomas S ^b   Scher, Evan S ^b   Pommier, Yves ^b   Cushman, Mark ^a  

^a PURDUE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(O FORMYLBENZOYL) PYRROLIDIN 3 OL; 1 (O AMINOPHENYL) 4 CHLORO 1 BUTANONE; 14 (1 IMIDAZOLYLMETHYL) 12H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE; 14 (DIMETHYLAMINOMETHYL) 2H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE; 14 (ETHANOLAMINOMETHYL) 2H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE; 14 (MORPHOLINOMETHYL) 2H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE; 14 [1 (METHYLPIPERAZINYLMETHYL) 2H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE; 14 [3 HYDROXYPYRROLIDINOMETHYL] 2H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE; 14 AZIDOMETHYL 12H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE; 14 AZIDOMETHYL 12H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE DIHYDROCHLORIDE; 14 CHLOROMETHYL 12H 5,11A DIAZADIBENZO[B,H]FLUOREN 11 ONE; 2 AMINO ALPHA CHLOROACETOPHENONE; 2,3 DIHYDROPYRROLOL[1,2 B]ISOQUINOLINE 1,5 DIONE; 3 CHLORO 1 (3H) ISOBENZOFURANONE; 3 PYRROLIDINONE ETHYLENE KETAL; AMINO ACID; AROMATHECIN; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ETHOXYCARBONYL 3 PYRROLIDINONE; ETHOXYCARBONYL 3 PYRROLIDINONE ETHYLENE KETAL; HYDROGEN; INDENOISOQUINOLINE; IRINOTECAN; ISOQUINOLINE DERIVATIVE; METHYLETHOXYCARBONYLGLYCINATE; PYRROLIDIN 3 OL HYDROGEN MALEATE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; DNA STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; PROTEIN LOCALIZATION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DNA TOPOISOMERASES, TYPE I; DRUG DESIGN; HUMANS; INDOLIZINES; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49449112587     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800259e     Document Type: Article

References (55)

1. Pommier, Y. Topoisomerase 1 inhibitors: camptothecins and beyond. Nat. Rev. Cancer. 2006, 6, 789-802.
2. Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3, 430-440.
3. Luzzio, M. J.; Besterman, J. M.; Emerson, D. L.; Evans, M. G.; Lackey, K.; Leitner, P. L.; McIntyre, G.; Morton, B.; Myers, P. L.; Peel, M.; Sisco, J. M.; Sternbach, D. D.; Tong, W.; Traesdale, A.; Uehling, D. E.; Vuong, A.; Yates, J. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J. Med. Chem. 1995, 38, 395-401.
4. Husain, I.; Mohler, J. L.; Seigler, H. F.; and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specficity and implications for cancer chemotherapy. Cancer. Res. 1994, 54 (2), 539-546.
5. Thomas, C. J.; Rahier, N. J.; Hecht, S. M. Camptothecin: current perspectives. Bioorg. Med. Chem. 2004, 12, 1585-1604.
6. Meng, L.-H.; Liao, Y.-Z.; Pommier, Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer chemotherapy. Curr. Top. Med. Chem. 2003, 3, 305-320.
7. Bailly, C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. 2000, 7, 39-58.
8. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88, 3888-3890.
9. Staker, B. L.; Hjerrild, K.; Feese, M. D.; Behnke, C. A.; Burgin, A. B.; Stewart, L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15387-15392.
10. Staker, B. L.; Feese, M. D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, L.; Burgin, A. Structures of three classes of anticancer agents bound to the human topoisomerase I - DNA covalent complex. J. Med. Chem. 2005, 48, 2336-2345.
11. Kohn, K. W.; Pommier, Y. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. Ann. N. Y. Acad. Sci. 2000, 922, 11-26.
12. Pommier, Y.; Pourquier, P.; Fan, Y.; Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400, 83-106.
13. Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Tele, C.; Moore, L.; Truesdale, A.; Leitner, P.; Besterman, J. M. Plant Antitumor Agents. 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem. 1993, 36, 2689-2700.
14. Xie, Z.; Ootsu, K.; and Akimoto, H. Convergent approach to water-soluble camptothecin derivatives. Bioorg. Med. Chem. Lett. 1995, 5 (19), 2189-2194.
15. Wani, M. C.; Nicholas, A. W.; Wall, M. E. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. J. Med. Chem. 1986, 29, 2358-2363.
16. Jew, S.-S.; Kim, M. G.; Kim, H.-J.; Rho, E.-Y.; Park, H.-G.; Kim, J.-K.; Han, H.-J.; Lee, H. Synthesis and in vitro cytotoxicity of C(20)(RS)- camptothecin analogues modified at both B (or A) and E ring. Bioorg. Med. Chem. Lett. 1998, 8, 1797-1800.
17. Ahn, S. K.; Choi, N. S.; Jeong, B. S.; Kim, K. K.; Journ, D. J.; Kim, J. K.; Lee, S. J.; Kim, J. W.; Hong, C. I.; Jew, S. Practical synthesis of (S)-7-(2-isopropylamino)ethylcamptothecin hydrochloride, potent topoisomerase I inhibitor. J. Heterocycl. Chem 2000, (Sep-Oct), 1141.
18. Wani, M. C.; Ronman, P. E.; Lindley, J. T.; Wall, M. E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J. Med. Chem. 1980, 23, 554-560.
19. Gottlieb, J. A.; Luce, J. K. Treatment of malignant melanoma with camptochecin (NSC-100880). Cancer Chemother. Rep. 1972, 56, 103-105.
20. Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E.; Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989, 49, 1465-1469.
21. Haas, N. B.; LaCreta, F. P.; Walczak, J.; Hudes, G. R.; Brennan, J. M.; Ozols, R. F.; O'Dwyer, P. J. Phase-I pharmacokinetic study of topotecan by 24-h continuous-infusion weekly. Cancer Res. 1994, 54 (5), 1220-1226.
22. Kohlhagen, G.; Pauli, K. D.; Cushman, M.; Nagafuji, P.; and Pommier, Y. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharm. 1998, 54, 50-58.
23. Nagarajan, M.; Morrell, A.; Fort, B. C.; Meckley, M. R.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings. J. Med. Chem. 2004, 47 (23), 5651-5661.
24. Morrell, A.; Placzek, M.; Parmley, S.; Grella, B.; Antony, S.; Pommier, Y.; Cushman, M. Optimization of the indenonone ring of indenoisoquinoline topoisomerase I inhibitors. J. Med. Chem. 2007, 50, 4388-4404.
25. Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3659-3663.
26. Antony, S.; Agama, K. K.; Miao, Z.-H.; Takagi, K.; Wright, M. H.; Robles, A. I.; Varticovski, L.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier, Y. Novel indenoisoquinolines NSC 725775 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res. 2007, 67 (21), 10397-10405.
27. Fox, B. M.; Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Staker, B. L.; Stewart, L.; Cushman, M. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J. Med. Chem. 2003, 46, 3275-3282.
28. Xiao, X.; Antony, S.; Pommier, Y.; Cushman, M. Total synthesis and biological evaluation of 22-hydroxyacuminatine. J. Med. Chem. 2006, 49, 1408-1412.
29. Pin, F.; Comesse, S.; Sanselme, M.; Daích, A. A domino N- amidoacylation/aldol-type condensation approach to the synthesis of the Topo-I inhibitor rosettacin and derivatives. J. Org. Chem. 2008, 73 (5), 1975-1978.
30. Cheng, K.; Rahier, N. J.; Eisenhauer, B. M.; Gao, R.; Thomas, S. J.; Hecht, S. M. 14-Azacamptothecin: a potent water-soluble topoisomerase I poison. J. Am. Chem. Soc. 2005, 127 (3), 838-839.
31. Cagir, A.; Jones, S. H.; Gao, R.; Eisenhauer, B. M.; Hecht, S. M.; Luotonin, A. A naturally occurring human DNA topoisomerase I poison. J. Am. Chem. Soc. 2003, 125, 13628-13629.
32. Cagir, A.; Eisenhauer, B. M.; Gao, R.; Jones, S. H.; Hecht, S. M. Synthesis and topoisomerase I inhibitory properties of luotonin A analogues. Bioorg. Med. Chem. 2004, 12, 6287-6299.
33. Mason, J. J.; Bergman, J. Total synthesis of luotonin A and 14-substituted analogues. Org. Biomol. Chem. 2007, 5, 2486-2490.
34. Dallavalle, S.; Merlini, L.; Beretta, G. L.; Tinelli, S.; Zunino, F. Synthesis and cytotoxic activity of substituted luotonin A derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 5757-5761.
35. Lin, L. Z.; Cordell, G. A. Quinoline alkaloids from Camptotheca acuminata. Phytochemistry 1989, 28, 1295-1297.
36. Shamma, M.; Novak, L. Synthetic approaches to camptothecin. Tetrahedron 1969, 25, 2275-2279.
37. Morrell, A.; Placzek, M. S.; Steffen, J. D.; Antony, S.; Agama, K.; Pommier, Y.; Cushman, M. Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures. J. Med. Chem. 2007, 50, 2040-2048.
38. Babjak, M.; Kanazawa, A.; Anderson, R. J.; Greene, A. E. Concise synthesis of 22-hydroxyacuminatine, cytotoxic camptothecinoid from Camptotheca acuminata, by pyridone benzannulation. Org. Biomol. Chem. 2006, 4, 407-409.
39. Zhou, H.-B.; Liu, G.-S.; Yao, Z.-J. Short and efficient total synthesis of luotonin A and 22-hydroxyacuminatine using a common cascade strategy. J. Org. Chem. 2007, 72, 6270-6272.
40. Bhaskar Kanth, J. V.; Periasamy, M. Convenient method for the synthesis of N-(ethyloxycarbonyl) ester derivatives from amino acids. Synth. Commun. 1995, 25, 1523-1530.
41. Dyke, S. F.; Sainsbury, M.; Evans, J. R. Lycorine: studies in synthesis. Tetrahedron 1973, 29, 213-220.
42. Roglans, A.; Marquet, J.; Moreno-Manas, M. Preparation of 3-pyrrolidone and 4-perhydroazepinone. Synth. Commun. 1992, 22, 1249-1258.
43. N2 reactions of amines with (acyloxy)alkyl α-halides: a product distribution study. J. Org. Chem. 1983, 48, 635-640.
44. Houghton, P. G.; Humphrey, G. R.; Kennedy, D. J.; Roberts, D. C.; Wright, S. H. B. Enantiospecific synthesis of the (4R)-1-azabicyclo[2.2.1] heptane ring system. J. Chem. Soc., Perkin Trans. 1 1993, 1421-1424.
45. Sugasawa, T.; Toyoda, T.; Adachi, M.; Sasakura, K. Aminohaloborane in organic synthesis. 1. Specific ortho substitution reaction of anilines. J. Am. Chem. Soc. 1978, 100, 4842-4852.
46. Cevasco, A. A. Process for the Manufacture of Cycloalkyl and Haloalkyl o-Aminophenyl Ketones. U.S. Patent 5,405,998, 1995.
47. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82 (13), 1107-1112.
48. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the national cancer institute in-vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91-109.
49. Antony, S.; Jayaraman, M.; Laco, G.; Kohlhagen, G.; Kohn, K. W.; Cushman, M.; Pommier, Y. Differential induction of topoisomerase I - DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerase I. Cancer Res. 2003, 63, 7428-7435.
50. Nagarajan, M.; Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I Inhibitors featuring polyamine side chains on the lactam nitrogen. J. Med. Chem. 2003, 46, 5712-5724.
51. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer. Inst. 1989, 81, 1088-1092.
52. Paull, K. D.; Hamel, E.; Malspeis, L. Prediction of Biochemical Mechanism of Action from the in Vitro Antitumor Screen of the National Cancer Institute. In Cancer Chemotherapeutic Agents; Foye, W. O., Ed.; American Chemical Society: Washington, DC, 1995; pp 9-45.
53. Delcros, J.-G.; Tomasi, S.; Carrington, S.; Martin, B.; Renault, J.; Blagbrough, I. S.; Uriac, P. Effect of spermine conjugation on the cytotoxicity and cellular transport of acridine. J. Med. Chem. 2002, 45, 5098-5111.
54. Garrett, S. W.; Davies, O. R.; Milroy, D. A.; Wood, P. J.; Pouton, C. W.; Threadgill, M. D. Synthesis and characterisation of polyamine-poly(ethylene glycol) constructs for DNA binding and gene delivery. Biooorg. Med. Chem. 2008, 8, 1779-1797.
55. Pourquier, P.; Ueng, L.-M.; Fertala, J.; Wang, D.; Park, H.-K.; Essigmann, J. M.; Bjornsti, M.-A.; Pommier, Y. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7,8-Dihydro-8-oxoguanine and 5-hydroxycytosine. J. Biol. Chem. 1999, 274, 8516-8523.